Skip to main content
. 2021 Oct 26;48(6):222. doi: 10.3892/ijmm.2021.5055

Figure 6.

Figure 6

ISLR promotes tumour progression and glycolysis of NSCLC cells by inactivating the IL-6/JAK/STAT3 pathway. (A and B) Gene set enrichment analysis results showing that the IL-6/JAK/STAT3 pathway was enriched in ISLR-related NSCLC. (C) Effect of ISLR knockdown on the levels of IL-6 in the cultural supernatants of NSCLC cell lines, as measured using ELISAs. (D) Effect of ISLR knockdown and overexpression on the phosphorylation levels of JAK2 and STAT3. *P<0.05 vs. control group; #P<0.05 vs. si-NC group; ^P<0.05 vs. pcDNA3.1-NC group. ISLR, immunoglobulin superfamily containing leucine-rich repeat; NC, negative control; si, small interfering RNA; NSCLC, non-small cell lung cancer; p-, phosphorylated.